Abstract 936P
Background
There are over 500,000 survivors of head and neck cancer (HNC) in the United States. While chronic pain is a common symptom across all cancer sites, we hypothesized it is more prevalent in HNC compared with other cancer sites, due to tumor location, treatment modality and functional impairment associated with HNC.
Methods
To compare self-reported chronic pain prevalence, we built a retrospective cohort of adult survivors with a history of cancer, using the National Health Interview Survey (NHIS) from 2010 to 2021. Study participants were grouped into HNC (n = 354) vs. other cancer survivors (n = 24,055), based on self-report of a previous cancer diagnosis. We estimated weighted prevalence rates of chronic pain in our sample, and in the final models, we estimated odds of reporting chronic pain while adjusting for sociodemographic (race, insurance, education, income, employment and smoking history) and clinical (depression, and self-rated health status) factors, using multivariate logistic regression analysis.
Results
Weighted, age-adjusted prevalence of chronic pain was significantly higher in HNC compared to other cancers (HNC = 45.5%, 95% CI: 42.6%, 48.5% vs. other cancers = 31.6%, 95% CI: 29.9%, 33.2%; p = 0.02). After adjusting for clinical and sociodemographic covariates, odds of reporting chronic pain remained significantly higher among HNC survivors compared to other cancers (aOR=1.34, 95% CI: 1.03, 1.75). Other factors associated with self-reported chronic pain included having depression (aOR=2.03, 95% CI: 1.90, 2.17), ≥ 65 years (aOR=0.74, 95% CI: 0.68, 0.80), being Hispanic (aOR=0.70, 95% CI:0.59, 0.83) compared to a non-Hispanic White, having private insurance (aOR=0.74, 95% CI: 0.69, 0.80), and education below high school level (aOR=1.39, 95% CI: 1.24, 1.56).
Conclusions
Chronic pain is highly prevalent among survivors of HNC, with almost 50% reporting chronic pain. Additionally, survivors of HNC are 34 percent more likely to report chronic pain compared to non-HNC survivors. Our findings highlight the burden of chronic pain in cancer, and the pressing need for effective pain management especially in HNC survivors.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03
1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony Tolcher
Session: Poster session 03